Literature DB >> 27006311

Inflammation: Species-specific TLR signalling -- insight into human disease.

Darren J Perkins1, Stefanie N Vogel1.   

Abstract

The selective utilization of IRAK kinases, which are thought to be recruited to MyD88 to form the ‘Myddosome’, has been shown to differ substantially in mouse and human cells. This finding has important implications for the development of therapeutics for inflammatory and autoimmune disorders associated with Toll-like receptors.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27006311      PMCID： PMC4955569          DOI： 10.1038/nrrheum.2016.36

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


  10 in total

Review 1.  Structural insights into the assembly of large oligomeric signalosomes in the Toll-like receptor-interleukin-1 receptor superfamily.

Authors:  Ryan Ferrao; Jixi Li; Elisa Bergamin; Hao Wu
Journal:  Sci Signal       Date:  2012-05-29       Impact factor: 8.192

Review 2.  Interleukin-1 receptor associated kinase inhibitors: potential therapeutic agents for inflammatory- and immune-related disorders.

Authors:  Malkeet Singh Bahia; Maninder Kaur; Pragati Silakari; Om Silakari
Journal:  Cell Signal       Date:  2015-02-27       Impact factor: 4.315

Review 3.  The interleukin-1 receptor-associated kinases: critical regulators of innate immune signalling.

Authors:  Sinead Flannery; Andrew G Bowie
Journal:  Biochem Pharmacol       Date:  2010-06-23       Impact factor: 5.858

4.  Cutting edge: expression of IL-1 receptor-associated kinase-4 (IRAK-4) proteins with mutations identified in a patient with recurrent bacterial infections alters normal IRAK-4 interaction with components of the IL-1 receptor complex.

Authors:  Andrei E Medvedev; Karen Thomas; Agnes Awomoyi; Douglas B Kuhns; John I Gallin; Xiaoxia Li; Stefanie N Vogel
Journal:  J Immunol       Date:  2005-06-01       Impact factor: 5.422

5.  Helical assembly in the MyD88-IRAK4-IRAK2 complex in TLR/IL-1R signalling.

Authors:  Su-Chang Lin; Yu-Chih Lo; Hao Wu
Journal:  Nature       Date:  2010-05-19       Impact factor: 49.962

6.  Primary immunodeficiency to pneumococcal infection due to a defect in Toll-like receptor signaling.

Authors:  Andrew J Currie; Donald J Davidson; Gregor S D Reid; Simi Bharya; Kelly L MacDonald; Rebecca S Devon; David P Speert
Journal:  J Pediatr       Date:  2004-04       Impact factor: 4.406

7.  Pyogenic bacterial infections in humans with IRAK-4 deficiency.

Authors:  Capucine Picard; Anne Puel; Marion Bonnet; Cheng-Lung Ku; Jacinta Bustamante; Kun Yang; Claire Soudais; Stéphanie Dupuis; Jacqueline Feinberg; Claire Fieschi; Carole Elbim; Remi Hitchcock; David Lammas; Graham Davies; Abdulaziz Al-Ghonaium; Hassan Al-Rayes; Sulaiman Al-Jumaah; Sami Al-Hajjar; Ibrahim Zaid Al-Mohsen; Husn H Frayha; Rajivi Rucker; Thomas R Hawn; Alan Aderem; Haysam Tufenkeji; Soichi Haraguchi; Noorbibi K Day; Robert A Good; Marie-Anne Gougerot-Pocidalo; Adrian Ozinsky; Jean-Laurent Casanova
Journal:  Science       Date:  2003-03-13       Impact factor: 47.728

8.  Comprehensive RNAi-based screening of human and mouse TLR pathways identifies species-specific preferences in signaling protein use.

Authors:  Jing Sun; Ning Li; Kyu-Seon Oh; Bhaskar Dutta; Sharat J Vayttaden; Bin Lin; Thomas S Ebert; Dominic De Nardo; Joie Davis; Rustam Bagirzadeh; Nicolas W Lounsbury; Chandrashekhar Pasare; Eicke Latz; Veit Hornung; Iain D C Fraser
Journal:  Sci Signal       Date:  2016-01-05       Impact factor: 8.192

9.  Inhibition of interleukin 1 receptor/Toll-like receptor signaling through the alternatively spliced, short form of MyD88 is due to its failure to recruit IRAK-4.

Authors:  Kimberly Burns; Sophie Janssens; Brian Brissoni; Natalia Olivos; Rudi Beyaert; Jürg Tschopp
Journal:  J Exp Med       Date:  2003-01-20       Impact factor: 14.307

10.  Distinct mutations in IRAK-4 confer hyporesponsiveness to lipopolysaccharide and interleukin-1 in a patient with recurrent bacterial infections.

Authors:  Andrei E Medvedev; Arnd Lentschat; Douglas B Kuhns; Jorge C G Blanco; Cindy Salkowski; Shuling Zhang; Moshe Arditi; John I Gallin; Stefanie N Vogel
Journal:  J Exp Med       Date:  2003-08-18       Impact factor: 14.307
  10 in total
  5 in total

1.  Human MYD88L265P is insufficient by itself to drive neoplastic transformation in mature mouse B cells.

Authors:  Tomasz Sewastianik; Maria Luisa Guerrera; Keith Adler; Peter S Dennis; Kyle Wright; Vignesh Shanmugam; Ying Huang; Helen Tanton; Meng Jiang; Amanda Kofides; Maria G Demos; Audrey Dalgarno; Neil A Patel; Anwesha Nag; Geraldine S Pinkus; Guang Yang; Zachary R Hunter; Petr Jarolim; Nikhil C Munshi; Steven P Treon; Ruben D Carrasco
Journal:  Blood Adv       Date:  2019-11-12

2.  Baicalin relieves Mycoplasma pneumoniae infection‑induced lung injury through regulating microRNA‑221 to inhibit the TLR4/NF‑κB signaling pathway.

Authors:  Han Zhang; Xiang Li; Juan Wang; Qi Cheng; Yunxiao Shang; Guizhen Wang
Journal:  Mol Med Rep       Date:  2021-06-10       Impact factor: 2.952

3.  Toll-like receptor agonist combinations augment mouse T-cell anti-tumor immunity via IL-12- and interferon ß-mediated suppression of immune checkpoint receptor expression.

Authors:  Donghwan Jeon; Douglas G McNeel
Journal:  Oncoimmunology       Date:  2022-03-21       Impact factor: 7.723

4.  p204 Is Required for Canonical Lipopolysaccharide-induced TLR4 Signaling in Mice.

Authors:  Young-Su Yi; Jinlong Jian; Elena Gonzalez-Gugel; Yong-Xiang Shi; Qingyun Tian; Wenyu Fu; Aubryanna Hettinghouse; Wenhao Song; Ronghan Liu; Michun He; Huabing Qi; Jing Yang; Xiaolan Du; GuoZhi Xiao; Lin Chen; Chuan-Ju Liu
Journal:  EBioMedicine       Date:  2018-02-16       Impact factor: 8.143

Review 5.  Kinase inhibition in autoimmunity and inflammation.

Authors:  Ali A Zarrin; Katherine Bao; Patrick Lupardus; Domagoj Vucic
Journal:  Nat Rev Drug Discov       Date:  2020-10-19       Impact factor: 84.694
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.